Disease · MONDO_0019954
Trials63
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 63
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00510068 | Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors | Phase 3 | 410 | 2011-12-15 | Advanced Neuroendocrine Tumors of Pancreatic Origin | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | Phase 3 | 171 | 2010-10-11 | Carcinoma, Islet Cell, Carcinoma, Pancreas | SUNITINIB MALATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | Phase 2 | 160 | 2012-03-30 | Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | Phase 2 | 160 | 2016-12-20 | Islet Cell Tumor | EVEROLIMUS, PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | Phase 2 | 150 | 2016-02-11 | Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma | BEVACIZUMAB, EVEROLIMUS, OCTREOTIDE ACETATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | Phase 2 | 144 | 2022-10-19 | Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma | CAPECITABINE, TEMOZOLOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years | 144 | 2023-11-13 | Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive | EVEROLIMUS, SUNITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02246127 | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor | Phase 3 | 141 | 2025-05-11 | Neuroendocrine Tumors | EVEROLIMUS, FLUOROURACIL, STREPTOZOCIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02549937 | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | Phase 1/2 | 130 | 2024-07-10 | Tumors | SURUFATINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02678780 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors | Phase 2 | 123 | 2025-07-24 | Neuroendocrine Tumors | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02282059 | The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors | 100 | 2024-06-20 | Pancreatic Neuroendocrine Tumors | SUNITINIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Phase 1/2 | 89 | 2021-12-14 | Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma | NENDRATAREOTIDE UZATANSINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | Phase 2 | 62 | 2016-04-07 | Pancreatic Neuroendocrine Tumors (pNET) | DACTOLISIB, EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | Phase 2 | 62 | 2022-07-01 | Neuroendocrine Cancer | CARFILZOMIB | Its record names the disease | ClinicalTrials.gov |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Phase 2 | 61 | 2023-07-20 | Carcinoid Tumor, Pancreatic Neuroendocrine Tumor | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Phase 2 | 60 | 2017-12-27 | Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor | GANITUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | Phase 2 | 52 | 2015-04-01 | Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor | OCTREOTIDE, PAZOPANIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | Phase 1/2 | 43 | 2020-07-09 | Pancreatic Neuroendocrine Tumor | EVEROLIMUS, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00869050 | Capecitabine and Temozolomide for Neuroendocrine Cancers | Phase 2 | 41 | 2016-06-22 | Neuroendocrine Tumors | CAPECITABINE, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | Phase 2 | 31 | 2016-05-02 | Pancreatic Neuroendocrine Tumors (pNET) | DACTOLISIB | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019954/trials